A detailed history of Barclays PLC transactions in Ocugen, Inc. stock. As of the latest transaction made, Barclays PLC holds 284,433 shares of OCGN stock, worth $281,588. This represents 0.0% of its overall portfolio holdings.

Number of Shares
284,433
Holding current value
$281,588
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.18 - $1.98 $335,630 - $563,177
284,433 New
284,433 $440,000
Q1 2023

May 04, 2023

SELL
$0.82 - $1.33 $965,210 - $1.57 Million
-1,177,086 Reduced 91.47%
109,802 $93,000
Q4 2022

Feb 13, 2023

BUY
$1.11 - $1.87 $93,957 - $158,288
84,646 Added 7.04%
1,286,888 $1.67 Million
Q3 2022

Nov 03, 2022

BUY
$1.75 - $3.1 $2.08 Million - $3.68 Million
1,188,660 Added 8751.73%
1,202,242 $2.14 Million
Q2 2022

Aug 12, 2022

BUY
$1.83 - $3.45 $24,855 - $46,857
13,582 New
13,582 $30,000

Others Institutions Holding OCGN

About Ocugen, Inc.


  • Ticker OCGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,566,000
  • Market Cap $214M
  • Description
  • Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...
More about OCGN
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.